Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Keating, M. J.
Right arrow Articles by McCredie, K. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Keating, M. J.
Right arrow Articles by McCredie, K. B.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Journal of Clinical Oncology, Vol 9, 44-49, Copyright © 1991 by American Society of Clinical Oncology

ARTICLES

Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia

MJ Keating, H Kantarjian, S O'Brien, C Koller, M Talpaz, J Schachner, CC Childs, EJ Freireich and KB McCredie
Department of Hematology, University of Texas MD Anderson Cancer Center, Houston 77030.

Thirty-three patients with chronic lymphocytic leukemia (CLL) with advanced Rai stage (III-IV) or progressive Rai stage (0-II) disease were treated with fludarabine as a single agent. Eleven patients (33%) obtained a complete remission (CR), 13 (39%) a clinical CR with residual nodules as the only evidence of disease (nodular partial remission [PR]), and two patients (6%) achieved a PR for a total response rate of 79%. Response was rapid, usually occurring after three to six courses of treatment. The major morbidity was infection. Febrile episodes occurred in 13% of the courses (pneumonia 6%, minor infection 4%, and transient fever of undocumented cause 3%). Fludarabine appears to be the most cytoreductive single agent so far studied in CLL.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
A.-M. Tsimberidou, S. Wen, P. McLaughlin, S. O'Brien, W. G. Wierda, S. Lerner, S. Strom, E. J Freireich, L. J. Medeiros, H. M. Kantarjian, et al.
Other Malignancies in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
J. Clin. Oncol., February 20, 2009; 27(6): 904 - 910.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
K. A. Foon, M. Boyiadzis, S. R. Land, S. Marks, A. Raptis, L. Pietragallo, D. Meisner, A. Laman, M. Sulecki, A. Butchko, et al.
Chemoimmunotherapy With Low-Dose Fludarabine and Cyclophosphamide and High Dose Rituximab in Previously Untreated Patients With Chronic Lymphocytic Leukemia
J. Clin. Oncol., February 1, 2009; 27(4): 498 - 503.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. M. Tsimberidou, S. Wen, S. O'Brien, P. McLaughlin, W. G. Wierda, A. Ferrajoli, S. Faderl, J. Manning, S. Lerner, C. V. Mai, et al.
Assessment of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma by Absolute Lymphocyte Counts in 2,126 Patients: 20 Years of Experience at The University of Texas M.D. Anderson Cancer Center
J. Clin. Oncol., October 10, 2007; 25(29): 4648 - 4656.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
N. E. Kay, S. M. Geyer, T. G. Call, T. D. Shanafelt, C. S. Zent, D. F. Jelinek, R. Tschumper, N. D. Bone, G. W. Dewald, T. S. Lin, et al.
Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia
Blood, January 15, 2007; 109(2): 405 - 411.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
T. D. Shanafelt, J. C. Byrd, T. G. Call, C. S. Zent, and N. E. Kay
Narrative review: initial management of newly diagnosed, early-stage chronic lymphocytic leukemia.
Ann Intern Med, September 19, 2006; 145(6): 435 - 447.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
N. Lamanna, M. Kalaycio, P. Maslak, J. G. Jurcic, M. Heaney, R. Brentjens, A. D. Zelenetz, D. Horgan, A. Gencarelli, K. S. Panageas, et al.
Pentostatin, Cyclophosphamide, and Rituximab Is an Active, Well-Tolerated Regimen for Patients With Previously Treated Chronic Lymphocytic Leukemia
J. Clin. Oncol., April 1, 2006; 24(10): 1575 - 1581.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. Chanan-Khan, K. C. Miller, K. Takeshita, A. Koryzna, K. Donohue, Z. P. Bernstein, A. Mohr, D. Klippenstein, P. Wallace, J. B. Zeldis, et al.
Results of a phase 1 clinical trial of thalidomide in combination with fludarabine as initial therapy for patients with treatment-requiring chronic lymphocytic leukemia (CLL)
Blood, November 15, 2005; 106(10): 3348 - 3352.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
T. S. Lin, M. R. Grever, and J. C. Byrd
Changing the Way We Think About Chronic Lymphocytic Leukemia
J. Clin. Oncol., June 20, 2005; 23(18): 4009 - 4012.
[Full Text] [PDF]

Home page
 JCOHome page
M. A. Weiss, P. G. Maslak, J. G. Jurcic, D. A. Scheinberg, T. B. Aliff, N. Lamanna, S. R. Frankel, S. E. Kossman, and D. Horgan
Pentostatin and Cyclophosphamide: An Effective New Regimen in Previously Treated Patients With Chronic Lymphocytic Leukemia
J. Clin. Oncol., April 1, 2003; 21(7): 1278 - 1284.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
S. N. O'Brien, N. M.A. Blijlevens, T. H. Mahfouz, and E. J. Anaissie
Infections in Patients with Hematological Cancer: Recent Developments
Hematology, January 1, 2003; 2003(1): 438 - 472.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. C. Byrd, B. L. Peterson, V. A. Morrison, K. Park, R. Jacobson, E. Hoke, J. W. Vardiman, K. Rai, C. A. Schiffer, and R. A. Larson
Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712)
Blood, January 1, 2003; 101(1): 6 - 14.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
V. A. Morrison, K. R. Rai, B. L. Peterson, J. E. Kolitz, L. Elias, F. R. Appelbaum, J. D. Hines, L. Shepherd, R. E. Martell, R. A. Larson, et al.
Impact of Therapy With Chlorambucil, Fludarabine, or Fludarabine Plus Chlorambucil on Infections in Patients With Chronic Lymphocytic Leukemia: Intergroup Study Cancer and Leukemia Group B 9011
J. Clin. Oncol., August 15, 2001; 19(16): 3611 - 3621.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
K. R. Rai, B. L. Peterson, F. R. Appelbaum, J. Kolitz, L. Elias, L. Shepherd, J. Hines, G. A. Threatte, R. A. Larson, B. D. Cheson, et al.
Fludarabine Compared with Chlorambucil as Primary Therapy for Chronic Lymphocytic Leukemia
N. Engl. J. Med., December 14, 2000; 343(24): 1750 - 1757.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
F. R. Mauro, R. Foa, D. Giannarelli, I. Cordone, S. Crescenzi, E. Pescarmona, R. Sala, R. Cerretti, and F. Mandelli
Clinical Characteristics and Outcome of Young Chronic Lymphocytic Leukemia Patients: A Single Institution Study of 204 Cases
Blood, July 15, 1999; 94(2): 448 - 454.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M.J. Keating, S. O'Brien, S. Lerner, C. Koller, M. Beran, L.E. Robertson, E. J Freireich, E. Estey, and H. Kantarjian
Long-Term Follow-Up of Patients With Chronic Lymphocytic Leukemia (CLL) Receiving Fludarabine Regimens as Initial Therapy
Blood, August 15, 1998; 92(4): 1165 - 1171.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
W. Knauf, B Ehlers, B Mohr, E Thiel, I Langenmayer, M Hallek, B Emmerich, D Adorf, C Nerl, and T Zwingers
Prognostic impact of the serum levels of soluble CD23 in B-cell chronic lymphocytic leukemia [letter]
Blood, June 1, 1997; 89(11): 4241 - 4056.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
P. Fidias, B. A. Chabner, and M. L. Grossbard
Purine Analogs for the Treatment of Low-Grade Lymphoproliferative Disorders
Oncologist, June 1, 1996; 1(3): 125 - 139.
[Abstract] [Full Text] [PDF]

Home page
 J Oncol Pharm PractHome page
J. M. Kolesar, A. K. Morris, and J. G. Kuhn
Review : Purine nucleoside analogues: Fludarabine, pentostatin, and cladribine: Part 1: Fludarabine
Journal of Oncology Pharmacy Practice, January 1, 1996; 2(3): 160 - 181.
[Abstract] [PDF]

Home page
 NEJMHome page
G. Juliusson, J. Liliemark, A. Saven, L. Piro, and S. O'Brien
2-Chlorodeoxyadenosine Therapy in Chronic Lymphocytic Leukemia
N. Engl. J. Med., June 23, 1994; 330(25): 1828 - 1830.
[Full Text]


About
JCO		 Editorial
Roster		 Advertising
Information		 Librarians &
Institutions		 Rights &
Permissions		 PDA Services

Copyright © 1991 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online